{
    "organizations": [],
    "uuid": "c28f5a1b9a1c8c8929c11be21ce20c93a16a735a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-matinas-biopharma-achieves-statist/brief-matinas-biopharma-achieves-statistical-endpoint-for-success-inphase-2a-clinical-study-of-orally-administered-mat2203-idUSFWN1P30IX",
    "ord_in_thread": 0,
    "title": "BRIEF-Matinas BioPharma Achieves Statistical Endpoint For Success In Phase 2a Clinical Study Of Orally-Administered MAT2203",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Matinas Biopharma Holdings Inc:\n* MATINAS BIOPHARMA ACHIEVES STATISTICAL ENDPOINT FOR SUCCESS IN PHASE 2A CLINICAL STUDY OF ORALLY-ADMINISTERED MAT2203 FOR THE TREATMENT OF CHRONIC REFRACTORY MUCOCUTANEOUS CANDIDIASIS\n* MATINAS BIOPHARMA - ‍INVESTIGATORS FROM NATIONAL INSTITUTES OF HEALTH RELAYED POSITIVE DATA FROM THIRD PATIENT ENROLLED IN PHASE 2A STUDY OF MAT2203​\n* MATINAS BIOPHARMA HOLDINGS INC - THE THIRD PATIENT MET PRIMARY ENDPOINT OF PHASE 2A STUDY WITH TREATMENT OF MAT2203​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:11:00.000+02:00",
    "crawled": "2018-01-09T17:11:41.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "matinas",
        "biopharma",
        "holding",
        "inc",
        "matinas",
        "biopharma",
        "achieves",
        "statistical",
        "endpoint",
        "success",
        "phase",
        "2a",
        "clinical",
        "study",
        "mat2203",
        "treatment",
        "chronic",
        "refractory",
        "mucocutaneous",
        "candidiasis",
        "matinas",
        "biopharma",
        "national",
        "institute",
        "health",
        "relayed",
        "positive",
        "data",
        "third",
        "patient",
        "enrolled",
        "phase",
        "2a",
        "study",
        "matinas",
        "biopharma",
        "holding",
        "inc",
        "third",
        "patient",
        "met",
        "primary",
        "endpoint",
        "phase",
        "2a",
        "study",
        "treatment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}